On March 13th, RudaCure and 翰林制药 held an advisory meeting for Phase 2 临床试验 of their 干眼症治疗药, inviting 13 ophthalmology clinical experts.
At the advisory meeting held at the Mondrian Hotel, with the assistance of 翰林制药's marketing department, 13 anterior segment ophthalmology professors from across the country were invited to share project descriptions and Phase 1 临床试验 progress for RCI001/HL262, and to receive advice for successfully conducting Phase 2 临床试验.
We sincerely thank all the professors and 翰林制药 colleagues who attended, and we will do our best to achieve results that meet everyone's expectations.